2025 Q4 -tulosraportti
3 päivää sitten
‧33 min
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 660 | - | - | ||
| 451 | - | - | ||
| 188 | - | - | ||
| 120 | - | - | ||
| 2 713 | - | - |
Ylin
4,595VWAP
Alin
4,375VaihtoMäärä
1,6 365 503
VWAP
Ylin
4,595Alin
4,375VaihtoMäärä
1,6 365 503
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 29.4. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 25.11.2025 | ||
2025 Q2 -tulosraportti 21.8.2025 | ||
2025 Q1 -tulosraportti 30.4.2025 | ||
2024 Q4 -tulosraportti 26.2.2025 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·2 päivää sittenStrong reaction, it was after all rather expected figures. Slightly low revenues but as most of us who own the stock, it is not this quarter that is decisive. It is the future that is bright and important.
·2 päivää sittenThere will be another issue but it usually isn't that negative after a couple of days
·2 päivää sittenso it wouldn't be so stupid of me to buy in now then maybe, what do you think per or the rest of you?- ·3 päivää sittenExciting with report tomorrow. Hoping for slightly increased revenues and good future prospects. Quiet period over and it will likely hail with insider purchases with the development that has been lately.
·17.2. · MuokattuDark day in the mine. Unfortunately fully invested. So far no large volume. That is probably the only bright spot.·17.2.I recognize the situation well. Nibe has at least broken upwards now. Hope it continues so I can free up some.- ·16.2. · MuokattuThe low share price is probably due to the continued after-effects of Pareto's catastrophic erroneous analysis at the end of November, where the analyst believed that there were already other products on the market that Egetis would have to compete with and lowered the price target to 1.60. A couple of days later, a price target came from Redeye, which apparently was around 13. Pareto's erroneous analysis basis, which many others fortunately objected to - but which Pareto has not corrected and acted upon - and which Nordnet unfortunately continues to disseminate as "lowest price target" instead of removing it, when it was demonstrably based on an error - or asking Pareto to withdraw their erroneous analysis. Furthermore, the situation was so abnormal - that rarely seen reactions were highly appropriate. I have never seen another research firm directly attack Pareto and their analysis basis, as we fortunately saw someone do in November. It was highly required and commendably fast - and completely unprecedented. If you have forgotten the matter, look at the posts below at the end of November. Here is an excerpt from Stiefel's correction, which shows Pareto's misconception - but see more below in November. Pareto on Wednesday lowered its recommendation for the stock to sell from hold with a price target reduction to 1:60 kronor from previously 6 kronor. In the (erroneous) analysis, Pareto wrote that an American price for Emcitate of 0.1 million dollars per year seems extremely high without any proven neurocognitive effect. Especially considering that there is a much cheaper alternative treatment (PTU+LT4) for thyrotoxicosis, a condition with an increased amount of thyroid hormone in the blood regardless of cause.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
3 päivää sitten
‧33 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·2 päivää sittenStrong reaction, it was after all rather expected figures. Slightly low revenues but as most of us who own the stock, it is not this quarter that is decisive. It is the future that is bright and important.·2 päivää sittenThere will be another issue but it usually isn't that negative after a couple of days·2 päivää sittenso it wouldn't be so stupid of me to buy in now then maybe, what do you think per or the rest of you?
- ·3 päivää sittenExciting with report tomorrow. Hoping for slightly increased revenues and good future prospects. Quiet period over and it will likely hail with insider purchases with the development that has been lately.
- ·17.2. · MuokattuDark day in the mine. Unfortunately fully invested. So far no large volume. That is probably the only bright spot.·17.2.I recognize the situation well. Nibe has at least broken upwards now. Hope it continues so I can free up some.
- ·16.2. · MuokattuThe low share price is probably due to the continued after-effects of Pareto's catastrophic erroneous analysis at the end of November, where the analyst believed that there were already other products on the market that Egetis would have to compete with and lowered the price target to 1.60. A couple of days later, a price target came from Redeye, which apparently was around 13. Pareto's erroneous analysis basis, which many others fortunately objected to - but which Pareto has not corrected and acted upon - and which Nordnet unfortunately continues to disseminate as "lowest price target" instead of removing it, when it was demonstrably based on an error - or asking Pareto to withdraw their erroneous analysis. Furthermore, the situation was so abnormal - that rarely seen reactions were highly appropriate. I have never seen another research firm directly attack Pareto and their analysis basis, as we fortunately saw someone do in November. It was highly required and commendably fast - and completely unprecedented. If you have forgotten the matter, look at the posts below at the end of November. Here is an excerpt from Stiefel's correction, which shows Pareto's misconception - but see more below in November. Pareto on Wednesday lowered its recommendation for the stock to sell from hold with a price target reduction to 1:60 kronor from previously 6 kronor. In the (erroneous) analysis, Pareto wrote that an American price for Emcitate of 0.1 million dollars per year seems extremely high without any proven neurocognitive effect. Especially considering that there is a much cheaper alternative treatment (PTU+LT4) for thyrotoxicosis, a condition with an increased amount of thyroid hormone in the blood regardless of cause.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 660 | - | - | ||
| 451 | - | - | ||
| 188 | - | - | ||
| 120 | - | - | ||
| 2 713 | - | - |
Ylin
4,595VWAP
Alin
4,375VaihtoMäärä
1,6 365 503
VWAP
Ylin
4,595Alin
4,375VaihtoMäärä
1,6 365 503
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 29.4. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 25.11.2025 | ||
2025 Q2 -tulosraportti 21.8.2025 | ||
2025 Q1 -tulosraportti 30.4.2025 | ||
2024 Q4 -tulosraportti 26.2.2025 |
2025 Q4 -tulosraportti
3 päivää sitten
‧33 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 29.4. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 25.11.2025 | ||
2025 Q2 -tulosraportti 21.8.2025 | ||
2025 Q1 -tulosraportti 30.4.2025 | ||
2024 Q4 -tulosraportti 26.2.2025 |
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·2 päivää sittenStrong reaction, it was after all rather expected figures. Slightly low revenues but as most of us who own the stock, it is not this quarter that is decisive. It is the future that is bright and important.·2 päivää sittenThere will be another issue but it usually isn't that negative after a couple of days·2 päivää sittenso it wouldn't be so stupid of me to buy in now then maybe, what do you think per or the rest of you?
- ·3 päivää sittenExciting with report tomorrow. Hoping for slightly increased revenues and good future prospects. Quiet period over and it will likely hail with insider purchases with the development that has been lately.
- ·17.2. · MuokattuDark day in the mine. Unfortunately fully invested. So far no large volume. That is probably the only bright spot.·17.2.I recognize the situation well. Nibe has at least broken upwards now. Hope it continues so I can free up some.
- ·16.2. · MuokattuThe low share price is probably due to the continued after-effects of Pareto's catastrophic erroneous analysis at the end of November, where the analyst believed that there were already other products on the market that Egetis would have to compete with and lowered the price target to 1.60. A couple of days later, a price target came from Redeye, which apparently was around 13. Pareto's erroneous analysis basis, which many others fortunately objected to - but which Pareto has not corrected and acted upon - and which Nordnet unfortunately continues to disseminate as "lowest price target" instead of removing it, when it was demonstrably based on an error - or asking Pareto to withdraw their erroneous analysis. Furthermore, the situation was so abnormal - that rarely seen reactions were highly appropriate. I have never seen another research firm directly attack Pareto and their analysis basis, as we fortunately saw someone do in November. It was highly required and commendably fast - and completely unprecedented. If you have forgotten the matter, look at the posts below at the end of November. Here is an excerpt from Stiefel's correction, which shows Pareto's misconception - but see more below in November. Pareto on Wednesday lowered its recommendation for the stock to sell from hold with a price target reduction to 1:60 kronor from previously 6 kronor. In the (erroneous) analysis, Pareto wrote that an American price for Emcitate of 0.1 million dollars per year seems extremely high without any proven neurocognitive effect. Especially considering that there is a much cheaper alternative treatment (PTU+LT4) for thyrotoxicosis, a condition with an increased amount of thyroid hormone in the blood regardless of cause.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 660 | - | - | ||
| 451 | - | - | ||
| 188 | - | - | ||
| 120 | - | - | ||
| 2 713 | - | - |
Ylin
4,595VWAP
Alin
4,375VaihtoMäärä
1,6 365 503
VWAP
Ylin
4,595Alin
4,375VaihtoMäärä
1,6 365 503
Välittäjätilasto
Dataa ei löytynyt